Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma.
作者信息
Gallamini Andrea
出版信息
Haematologica. 2010 Jul;95(7):1046-8. doi: 10.3324/haematol.2010.024885.
Abstract
摘要
相似文献
1
Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma.
Haematologica. 2010 Jul;95(7):1046-8. doi: 10.3324/haematol.2010.024885.
2
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
Am J Med. 2002 Mar;112(4):262-8. doi: 10.1016/s0002-9343(01)01117-2.
3
Negative PET: good prognosis for Hodgkin's lymphoma.
Lancet Oncol. 2015 Jun;16(6):e265. doi: 10.1016/S1470-2045(15)70210-X. Epub 2015 Apr 30.
4
The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Hematology. 2003 Dec;8(6):403-8. doi: 10.1080/1024533032000158841.
5
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
Lancet Oncol. 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22.
6
Hodgkin's and non-Hodgkin's lymphomas.
Radiol Clin North Am. 2007 Jan;45(1):69-83. doi: 10.1016/j.rcl.2006.10.006.
7
Negative PET: no guarantee of good prognosis in Hodgkin's lymphoma.
Ann Hematol. 2015 Sep;94(9):1609-10. doi: 10.1007/s00277-015-2424-x. Epub 2015 Jun 14.
8
Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.
Curr Probl Diagn Radiol. 2006 Jul-Aug;35(4):151-63. doi: 10.1067/j.cpradiol.2006.02.001.
9
Hodgkin's lymphoma--patient's assessment and staging.
Cancer J. 2009 Mar-Apr;15(2):138-42. doi: 10.1097/PPO.0b013e3181a27146.
10
Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Oncologist. 2009;14 Suppl 2:30-40. doi: 10.1634/theoncologist.2009-S2-30.
引用本文的文献
1
Baseline IgM Amounts Can Identify Patients with Poor Outcomes: Results from a Real-Life Single-Center Study on Classical Hodgkin Lymphoma.
Cancers (Basel). 2024 Feb 18;16(4):826. doi: 10.3390/cancers16040826.
2
Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach.
Chemotherapy. 2024;69(1):1-10. doi: 10.1159/000533766. Epub 2023 Sep 14.
3
Misinterpretation of an inflammatory FDG uptake in a patient treated for Hodgkin lymphoma: a case report.
Asia Ocean J Nucl Med Biol. 2023;11(2):171-174. doi: 10.22038/AOJNMB.2022.66011.1457.
4
Limited benefit of additional contrast-enhanced CT to end-of-treatment PET/CT evaluation in patients with follicular lymphoma.
Sci Rep. 2021 Sep 16;11(1):18496. doi: 10.1038/s41598-021-98081-x.
5
Myocardial Metabolic Response Predicts Chemotherapy Curative Potential on Hodgkin Lymphoma: A Proof-of-Concept Study.
Biomedicines. 2021 Aug 6;9(8):971. doi: 10.3390/biomedicines9080971.
6
FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma.
Cancers (Basel). 2021 Aug 5;13(16):3952. doi: 10.3390/cancers13163952.
7
[The prognostic significance of peripheral lymphocyte/monocyte ratio and PET-2 evaluation in adult Hodgkin's lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2019 May 14;40(5):372-377. doi: 10.3760/cma.j.issn.0253-2727.2019.05.005.
8
The role of FDG-PET in Hodgkin lymphoma.
Contemp Oncol (Pozn). 2017;21(2):104-114. doi: 10.5114/wo.2017.68618. Epub 2017 Jun 30.
9
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients.
Br J Haematol. 2018 Feb;180(4):600-602. doi: 10.1111/bjh.14406. Epub 2016 Oct 26.
10
The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.
Oncotarget. 2016 Oct 11;7(41):67333-67346. doi: 10.18632/oncotarget.12024.
本文引用的文献
1
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.
Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1824-33. doi: 10.1007/s00259-010-1490-5. Epub 2010 May 27.
2
A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma.
Haematologica. 2010 Jul;95(7):1198-206. doi: 10.3324/haematol.2009.016105. Epub 2010 Apr 21.
3
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
N Engl J Med. 2010 Mar 11;362(10):875-85. doi: 10.1056/NEJMoa0905680.
4
Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation.
Leuk Lymphoma. 2009 Nov;50(11):1761-4. doi: 10.3109/10428190903308072.
5
Report on the First International Workshop on Interim-PET-Scan in Lymphoma.
Leuk Lymphoma. 2009 Aug;50(8):1257-60. doi: 10.1080/10428190903040048.
6
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.
Blood. 2009 Jun 18;113(25):6392-402. doi: 10.1182/blood-2009-03-209650. Epub 2009 Apr 17.
7
Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
J Clin Oncol. 2009 Apr 10;27(11):1906-14. doi: 10.1200/JCO.2008.16.0861. Epub 2009 Mar 9.
8
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.
Ann Oncol. 2009 Jul;20(7):1270-4. doi: 10.1093/annonc/mdn768. Epub 2009 Feb 19.
9
Stromal gene signatures in large-B-cell lymphomas.
N Engl J Med. 2008 Nov 27;359(22):2313-23. doi: 10.1056/NEJMoa0802885.
10
Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma.
Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1413-20. doi: 10.1007/s00259-008-0787-0.
Zotero 插件